Nexstim Plc: Managers’ Transactions, Hildén
Company Announcement, Helsinki, 22 May 2023 at 12:30PM(EEST)
Nexstim Plc: Managers’ Transactions, Hildén
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces managers’ transactions as follows:
Person subject to the notification requirement
Name: Timo Hildén
Position: Member of the Board/Deputy member
Issuer: Nexstim Oyj
LEI: 743700S7ZI0LNMHZ6Y27
Notification type: INITIAL NOTIFICATION
Reference number: 32104/4/4
____________________________________________
Transaction date: 2023-05-19
Outside a trading venue
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
Name of the instrument: 2023H
Nature of transaction: ACCEPTANCE OF A STOCK OPTION
(X) Linked to stock option programme
Transaction details
(1): Volume: 8500 Unit price: 0 EUR
Aggregated transactions (1):
Volume: 8500 Volume weighted average price: 0 EUR
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com
The Company’s Certified Advisor is Erik Penser Bank.
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Lassila & Tikanoja plc: Interim Report 1 January–31 March 202426.4.2024 07:00:00 CEST | Press release
Lassila & Tikanoja plc Stock exchange release 26 April 2024 at 8:00 a.m. Lassila & Tikanoja plc: Interim Report 1 January–31 March 2024 STABLE RESULT IN THE FINNISH DIVISIONS – FACILITY SERVICES SWEDEN DID NOT MEET EXPECTATIONS Unless otherwise mentioned, the figures in brackets refer to the corresponding period in the previous year. Net sales for the first quarter were EUR 185.0 million (192.7). Net sales decreased by 4.0%. The decline in net sales was due to the weak economic environment.Adjusted operating profit was EUR 0.0 million (1.4) and operating profit was EUR -1.7 million (1.4). Earnings per share were EUR -0.02 (0.03). Net cash flow from operating activities after investments was EUR -9.4 million (19.2) and net cash flow from operating activities after investments per share was EUR -0.25 (0.50). Net cash flow was negatively impacted by the reduction in factoring. Outlook for the year 2024 Net sales in 2024 are estimated to be at the same level as in the previous year, and op
Hexatronic Group AB (publ) Interim report January – March 202426.4.2024 07:00:00 CEST | Press release
Hexatronic Group AB (publ) Interim report January – March 2024 Continued strong operating cash flow and contribution from new focus areas First quarter (January 1 – March 31, 2024) Net sales decreased by 16 percent to MSEK 1,782 (2,115). Sales decreased organically by 27 percent.EBITA decreased by 54 percent to MSEK 168 (365), corresponding to an EBITA margin of 9.4 percent (17.2).Operating profit (EBIT) decreased by 59 percent to MSEK 138 (340), corresponding to an operating margin of 7.7 percent (16.1).Net profit decreased by 73 percent to MSEK 61 (224).Earnings per share after dilution amounted to SEK 0.31 (1.09).Leverage ratio (net debt/EBITDA (pro forma), R12) amounted to 2.0x compared to 1.7x as of December 31, 2023.Cash flow from operating activities amounted to MSEK 270 (28). Significant events during the quarter The Board of Directors proposes to the Annual General Meeting that no payment of dividend will be made for the financial year 2023.Hexatronic merges its two Swedish wh
IMCD reports EBITA of EUR 127 million in the first three months of 202426.4.2024 07:00:00 CEST | Press release
Rotterdam, The Netherlands (26 April 2024) - IMCD N.V. (“IMCD” or “Company”), a global leading distribution partner, and formulator of speciality chemicals and ingredients, today announces its first three months 2024 results. HIGHLIGHTS Gross profit of EUR 295 million (on a constant currency basis, equal to the first three months of 2023)Operating EBITA decline of 15% to EUR 127 million (-13% on a constant currency basis)Free cash flow of EUR 106 million (first three months of 2023: EUR 147 million)Cash earnings per share decline of 19% to EUR 1.41 (first three months of 2023: EUR 1.74)Successful completion of six acquisitions: Valuetree and CJ Shah in India, Joli Foods in Colombia, RBD in China, Euro Chemo-Pharma/Biofresh in Malaysia and Gova in the Benelux Valerie Diele-Braun, CEO: "In a volatile first quarter of the year, we faced challenging conditions in some of our market segments, resulting in a lower operating EBITA of EUR 127 million versus a very strong Q1 2023. Whilst our ac
Kitron: Ex dividend NOK 0.75 today26.4.2024 07:00:00 CEST | Press release
The shares in Kitron ASA will be traded ex dividend NOK 0.75 as from today, 26.04.2024. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Signify reports first quarter sales of EUR 1.5 billion, operational profitability of 8.3% and a free cash flow of EUR 80 million26.4.2024 07:00:00 CEST | Press release
Press Release April 26, 2024 Signify reports first quarter sales of EUR 1.5 billion, operational profitability of 8.3% and a free cash flow of EUR 80 million First quarter 20241 Signify's installed base of connected light points increased from 124 million in Q4 23 to 126 million in Q1 24Achieved reasonable assurance on full Brighter Lives, Better World 2025 program, including scope 3 emissionsSales of EUR 1,468 million; nominal sales decline of -12.5% and CSG of -10.1%LED-based sales represented 87% of total sales (Q1 23: 82%)Adj. EBITA margin of 8.3% (Q1 23: 8.9%)Net income of EUR 44 million (Q1 23: EUR 28 million)Free cash flow of EUR 80 million (Q1 23: EUR 51 million) Eindhoven, the Netherlands – Signify (Euronext: LIGHT), the world leader in lighting, today announced the company’s first quarter 2024 results. “In the first quarter, we saw improving dynamics in our US Professional, OEM and Consumer businesses, while the market in China remained soft and the European Professional busi